首页> 外文期刊>Research and practice in thrombosis and haemostasis. >Design strategy of antidote sequence for bivalent aptamer: Rapid neutralization of high-anticoagulant thrombin-binding bivalent DNA aptamer-linked M08 with HD22
【24h】

Design strategy of antidote sequence for bivalent aptamer: Rapid neutralization of high-anticoagulant thrombin-binding bivalent DNA aptamer-linked M08 with HD22

机译:二价适体的解毒序列设计策略:高抗凝凝血酶结合二价DNA适体 - 连接M08的快速中和HD22

获取原文
           

摘要

Background Bivalent thrombin-binding aptamers (TBAs) have great potential for the treatment of thrombosis because they exhibit high anticoagulant activity, and their complementary single-stranded DNA (ssDNA) sequences work as an antidote. However, a design strategy for antidote sequences against bivalent aptamers has not been established. Objectives To develop bivalent TBAs using M08, which exhibits higher anticoagulant activity than the previously reported exosite Ⅰ–binding DNA aptamers, such as HD1, an exosite Ⅱ–binding DNA aptamer (HD22) was linked to M08 with various types of linkers. In addition, short-length complementary ssDNAs were designed to neutralize the optimized bivalent aptamer effectively and rapidly. Results Among the bivalent aptamers of M08 linked to HD22 with various types of linkers, M08-T15-HD22 possessed approximately 5-fold higher anticoagulant activity than previously reported bivalent aptamers. To neutralize the activity of the 87-meric M08-T15-HD22, complementary ssDNA sequences with different lengths and hybridization segments were designed. The complementary sequence against the M08 moiety played a more important role in neutralizing than that against the HD22 moiety. Hybridization of the T15 linker in the M08-T15-HD22 with the A15 sequence in the antidote accelerated neutralization due to toehold-mediated strand displacement. Interestingly, some shorter-length antidotes showed higher neutralizing activity than the full complementary 87-meric antidote, and the shortest, 34-meric antidote, neutralized most effectively. Conclusions A pair comprising an 87-meric bivalent TBA containing M08 and a 34-meric short-length antidote with high anticoagulant and rapid neutralizing activities was developed. This design strategy of the DNA sequence can be used for other bivalent DNA aptamers and their antidotes.
机译:背景技术二价凝血酶结合适体(TBA)具有巨大的血栓形成潜力,因为它们表现出高抗凝活性,并且它们的互补的单链DNA(SSDNA)序列作为解毒剂工作。然而,尚未建立针对二价适体的解毒序列的设计策略。使用M08开发二价TBA的目的,其表现出比先前报道的抗凝血活性更高的抗凝血活性,例如HD1,以HD1,乳房Ⅱ结合DNA适体(HD22)与各种类型的接头连接到M08。此外,简短的互补SSDNA旨在有效且快速地中和优化的二价适体。结果与各种类型的接头连接到HD22的M08的二价适体中,M08-T15-HD22具有比先前报道的二价适体的抗凝血活性约为5倍。为了中和87mericM08-T15-HD22的活性,设计了具有不同长度和杂交段的互补的SSDNA序列。对M08部分的互补序列在中和而不是抵抗HD22部分的中和中的作用更重要。由于朝多克罗盛介导的链位移引起的解毒剂加速中和中的A15序列,T15接头在M08-T15-HD22中的杂交。有趣的是,一些较短的较短的解毒剂表现出比完整的互补87级解毒剂更高的中和活动,以及最短的34米的解毒剂,最有效地中和。结论,含有含有M08的87级二价TBA的一对,具有高抗凝剂和快速中和活性的34级短度引用。 DNA序列的这种设计策略可用于其他二价DNA适体及其解毒剂。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号